RCI Banque: Third supplement to the base prospectus EMTN 2021
September 6th, 2022
A third supplement to RCI Banque EMTN Programme Base Prospectus, dated November 10th, 2021, is now available on the website www.mobilize-fs.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ændringer i afdelinger i Værdipapirfonden Sparinvest, herunder suspensioner19.4.2024 13:48:55 CEST | pressemeddelelse
Bestyrelsen i Sparinvest S.A. har på vegne af Værdipapirfonden Sparinvest den 18. december 2023 besluttet at foretage ændringer i afdelingerne Nye obligationsmarkeder og Nye obligationsmarkeder Akk. Ændringerne medfører skift af afdelingsnavn, benchmark og strategi. Efter ændringerne vil afdelingerne udelukkende investere i emerging markets obligationsudstedelser i lokal valuta, og afdelingernes benchmark ændres til: J.P. Morgan ESG GBI-EM (Unhedged in DKK) Custom Index - Nykredit Exclusion List. ISINAfdelingsnavn før ændringAfdelingsnavn efter ændringSpecifikationerDK0060254043Nye obligationsmarkederINDEX Emerging Market Bonds LokalvalutaBørsnoteretDK0060254126Nye obligationsmarkeder Akk. – KL AINDEX Emerging Market Bonds Lokalvaluta Akk. – KL ABørsnoteretDK0062263372Nye obligationsmarkeder Akk. – KL WINDEX Emerging Market Bonds Lokalvaluta Akk. – KL WUnoteret Bestyrelsen i Sparinvest S.A. har på vegne af Værdipapirfonden Sparinvest den 18. december 2023 besluttet at stifte to nye afd
Auction result of Treasury Bonds - RIKB 27 041519.4.2024 13:30:00 CEST | Press release
Series RIKB 27 0415Settlement Date 04/24/2024Total Amount Allocated (MM) 15,129All Bids Awarded At (Price / Yield) 99.293/8.270Total Number of Bids Received 61Total Amount of All Bids Received (MM) 18,679Total Number of Successful Bids 45Number of Bids Allocated in Full 45Lowest Price / Highest Yield Allocated 99.293/8.270Highest Price / Lowest Yield Allocated 99.750/8.090Lowest Price / Highest Yield Allocated in Full 99.293/8.270Weighted Average of Successful Bids (Price/Yield) 99.471/8.200Best Bid (Price / Yield) 99.750/8.090Worst Bid (Price / Yield) 98.876/8.440Weighted Average of All Bids Received (Price / Yield) 99.422/8.220Percentage Partial Allocation (Approximate) 100.00 %Bid to Cover Ratio 1.23
Netcompany - Final transactions in connection with share buyback programme19.4.2024 13:17:11 CEST | Press release
Company announcement No. 17/2024 19 April 2024 Final transactions in connection with share buyback programme On 25 January 2024, Netcompany Group A/S (“Netcompany”) announced that a share buyback programme of up to DKK 150m and a maximum of 1,300,000 shares had been initiated with the purpose of initiating the redistribution of DKK 2bn to shareholders in line with the midterm 2026 targets. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme was set to end no later than 1 May 2024. Today, Netcompany announces the final transactions carried out under the current share buyback programme. The following transactions have been executed in the period 16 April 2024 to 18 April 2024: Number of shares Average purchase price, DKK Transaction value, DKK 16-04-2024 20,000 258.0
The deadline for Valoe’s restructuring programme extended until 14.6.2024. Valoe has secured financing for the duration of the proceedings and continues to negotiate longer-term financing.19.4.2024 13:05:00 CEST | Press release
Valoe Corporation Stock Exchange Release 19 April 2024 at 14.05 Finnish time The deadline for Valoe’s restructuring programme extended until 14.6.2024. Valoe has secured financing for the duration of the proceedings and continues to negotiate longer-term financing. Valoe Corporation's ("the Company") restructuring proceedings commenced on 22 January 2024 by the decision of the District Court of North Savo. In accordance with the request of the administrator Pekka Jaatinen, the District Court has extended the deadline for submitting a draft restructuring programme for Valoe until 14 June 2024. The original deadline for submitting a draft restructuring programme was 22 April 2024. Valoe has secured funding for the duration of the restructuring proceedings. The company is actively negotiating long-term financing and ownership arrangements with several parties. The Company's projects with key customers continue as normal. In Mikkeli, 19 April 2024 Valoe Corporation Board of Directors For m
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 202419.4.2024 13:00:00 CEST | Press release
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers